Stressgen (VSE: SSB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: William Marsh who wrote (88)	8/3/1999 6:18:00 PM
From: Heat Shock	Read Replies (1) of 236

William, I thought the thread might enjoy the following peculiar question and answer. I recently emailed Stressgen IR person Michelle with a few questions and here is one of them followed by her reply. Stressgen CEO Richard Glickman was scheduled to talk at some conference about creative financing for biotechs. Michael Milken has prostate cancer, is looking to help research into this condition and has lots of money. Stressgen's list of product candidates in the last annual report now includes prostate cancer. I read in a biotech discussion thread the concept of a wealthy individual handing over, say, 50 million dollars to a biotech for action on a specific indication in exchange for getting a compassionate use of the therapy. What is Stressgen's position on such creative financing mechanisms? StressGen explores various financing options on a regular basis and pursues those which best fit with the company's overall strategy. Heat

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next